MedTrace Logo

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

NCT03159403 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 325

Last updated 2018-03-12

No results posted yet for this study

Summary

This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.

Conditions

  • Gram-Positive Bacterial Infections

Interventions

DRUG

Oritavancin

This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.

Sponsors & Collaborators

  • Melinta Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Information · Global Health Science Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-12
Primary Completion
2018-02-15
Completion
2018-03-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03159403 on ClinicalTrials.gov